Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)

Next Previous
Trial Profile

Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Canakinumab (Primary)
  • Indications COVID-19 pneumonia; Cytokine release syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms CAN-COVID
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 20 Jul 2021 Interim results of final analysis of performed after all patients completed day 29, when the primary and secondary end points were analyzed published in the JAMA: the Journal of the American Medical Association
  • 09 Feb 2021 Status changed from active, no longer recruiting to completed.
  • 06 Nov 2020 According to a Novartis media release, this interim results from this study will be submitted to a peer-reviewed journal in the coming weeks.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top